scholarly journals Phase II Trial of Graft-versus-Host Disease Prophylaxis with Post-Transplantation Cyclophosphamide after Reduced-Intensity Busulfan/Fludarabine Conditioning for Hematological Malignancies

2015 ◽  
Vol 21 (5) ◽  
pp. 906-912 ◽  
Author(s):  
Amin M. Alousi ◽  
Jonathan E. Brammer ◽  
Rima M. Saliba ◽  
Borje Andersson ◽  
Uday Popat ◽  
...  
Keyword(s):  
Phase Ii ◽  
Graft Versus Host Disease ◽  
Hematological Malignancies ◽  
Phase Ii Trial ◽  
Post Transplantation ◽  
Host Disease ◽  
Graft Versus Host ◽  
Reduced Intensity

scholarly journals Ixazomib for Treatment of Refractory Chronic Graft-versus-Host Disease: A Chronic GVHD Consortium Phase II Trial

2020 ◽  
Vol 26 (9) ◽  
pp. 1612-1619
Author(s):  
Joseph Pidala ◽  
Vijaya R. Bhatt ◽  
Betty Hamilton ◽  
Iskra Pusic ◽  
William A. Wood ◽  
...  
Keyword(s):  
Phase Ii ◽  
Graft Versus Host Disease ◽  
Phase Ii Trial ◽  
Chronic Gvhd ◽  
Host Disease ◽  
Graft Versus Host

Prolonged Survival in Adults with Acute Lymphoblastic Leukemia (ALL) Following Reduced Intensity Conditioning and Allogeneic Transplantation

Blood ◽  
2008 ◽  
Vol 112 (11) ◽  
pp. 4415-4415
Author(s):  
Veronika Bachanova ◽  
Daniel J. Weisdorf ◽  
Claudio Brunstein ◽  
John Wagner ◽  
Michael Verneris
Keyword(s):  
Graft Versus Host Disease ◽  
Kinase Inhibitors ◽  
Hematopoietic Cell Transplantation ◽  
Lymphoblastic Leukemia ◽  
Reduced Intensity Conditioning ◽  
Post Transplantation ◽  
Host Disease ◽  
Graft Versus Host ◽  
Allogeneic Hct ◽  
Reduced Intensity

Abstract Reduced intensity conditioning (RIC) and allogeneic hematopoietic cell transplantation (HCT) for adult patients with ALL may improve the tolerance and outcomes following allografting. We studied 22 consecutive patients (2001–2008) who received RIC HCT. Indications for RIC regimens included: age > 55 years (for matched related donor [MRD], >45 years for unrelated or umbilical cord [UCB]), Karnofsky index <80%, impaired organ function or prior autologous/allogeneic HCT. The median age was 49 years (24–68), median diagnostic WBC 20×109/L (1.4–248) and median comorbidity index of 3 (range: 0–8) at HCT. All patients had high risk disease, including 14 patients (64%) with Ph+ ALL, 10 patients (46%) in 2nd or subsequent remission. Five patients (23%) were treated with tyrosine kinase inhibitors pre-HCT. Uniform conditioning (Cyclophosphamide 50 mg/kg; Flu 200 mg/m2; total body irradiation (TBI) 200cGy, n=21) and graft versus host disease (GvHD) prophylaxis (Cyclosporin/MMF) was followed by MRD (n=4) or UCB donor (n=18) grafts. All patients had sustained donor neutrophil engraftment (median 10 days, range 0–28) and reached 100% donor chimerism at median day 23 post-transplantation (range 14–99 days). At 3 years, treatment related morality relapse and overall survival (OS) were 27% (95% confidence interval [CI]: 9–45%), 36% (95% CI: 14–58%) and 50% (95% CI: 27–73%), respectively. There were no relapses beyond 2 years. After a median follow-up of 33 months (range 5–77) the cumulative incidence of acute II–IV, III–IV and chronic graft versus host disease were 55%, 20% and 45%. Lower TRM for HCT in CR1 vs ≥ CR2 (8% vs. 50%; p<0.04) led to improved 3 year OS in the CR1 cohort (81% vs. 15% (p<0.01)). HCT using either MRD or UCB resulted in similar risks of GVHD, relapse and OS. These data suggest that RIC allogeneic HCT using either related or UCB donors for adults with ALL can result in modest TRM, and only limited risks of relapse and promising leukemia-free survival. Further study, especially for patients in CR1, will better define the utility of this approach for patients unsuited for more intensive, myeloablative conditioning.

scholarly journals Carfilzomib for Treatment of Refractory Chronic Graft-versus-Host Disease: A Chronic GVHD Consortium Pilot Phase II Trial

2020 ◽  
Vol 26 (2) ◽  
pp. 278-284 ◽  
Author(s):  
Joseph Pidala ◽  
Samantha Jaglowski ◽  
Annie Im ◽  
George Chen ◽  
Lynn Onstad ◽  
...  
Keyword(s):  
Phase Ii ◽  
Graft Versus Host Disease ◽  
Phase Ii Trial ◽  
Chronic Gvhd ◽  
Pilot Phase ◽  
Host Disease ◽  
Graft Versus Host
Sign in / Sign up

Export Citation Format

Share Document